Aquilo Partners LP
Independent investment bank focused on strategic and financial advisory for life science companies. Provides tailored services including M&A, licensing/partnering, private placements, and transaction structuring, leveraging sector-specific experience, financial analysis, and a global network to support corporate and financing transactions.
Industries
Nr. of Employees
small (1-50)
Aquilo Partners LP
San Francisco, California, United States, North America
Services
Advisory on buy-side and sell-side mergers and acquisitions, including valuation, buyer/target identification, and transaction execution.
Advisory on licensing deals, options, platform collaborations and partnership economics across development stages.
Raising private capital via placement with institutional and strategic investors; management of investor diligence and deal logistics.
Advisory services to clarify positioning, value creation pathways, strategic optionality, and to support negotiation and closing.
Advisory on buy-side and sell-side mergers and acquisitions, including valuation, buyer/target identification, and transaction execution.
Advisory on licensing deals, options, platform collaborations and partnership economics across development stages.
Raising private capital via placement with institutional and strategic investors; management of investor diligence and deal logistics.
Advisory services to clarify positioning, value creation pathways, strategic optionality, and to support negotiation and closing.
Expertise Areas
- Mergers & acquisitions advisory
- Licensing and strategic partnerships
- Private placements and capital raising
- Transaction structuring and negotiation
Key Technologies
- Financial modeling
- Valuation analysis
- Market intelligence and competitive analysis
- Deal sourcing and outreach methodologies
News & Updates
Advised on sale of a preclinical company developing a platform technology to Eli Lilly for $1B+.
Advised on a global partnership between a therapeutics company and AbbVie for $335m+ focused on oncology and autoimmune indications.
Advised on licensing agreement with a major pharmaceutical company for an FDA-approved antifungal treatment valued at $593m+.
Advised on an option-to-license agreement with a pharmaceutical company valued at $400m+ for an ophthalmology therapeutic program.
Advised on sale of a single-cell spatial biology tools company to a life sciences buyer.
Advised on a Series C financing round that included participation from a strategic pharmaceutical investor.
Advised on sale of a preclinical company developing a platform technology to Eli Lilly for $1B+.
Advised on a global partnership between a therapeutics company and AbbVie for $335m+ focused on oncology and autoimmune indications.
Advised on licensing agreement with a major pharmaceutical company for an FDA-approved antifungal treatment valued at $593m+.
Advised on an option-to-license agreement with a pharmaceutical company valued at $400m+ for an ophthalmology therapeutic program.
Advised on sale of a single-cell spatial biology tools company to a life sciences buyer.
Advised on a Series C financing round that included participation from a strategic pharmaceutical investor.